Treatment	O
of	O
Carcinoma	B:C0686217
In	I:C0686217
Situ	I:C0686217
of	I:C0686217
the	I:C0686217
Glans	I:C0686217
Penis	I:C0686217
With	O
Topical	O
Imiquimod	O
Followed	O
by	O
Carbon	O
Dioxide	I:C0392251
Laser	I:C0392251
Excision	O
.	O

Treatment	O
of	O
Carcinoma	O
In	I:C0686217
Situ	I:C0686217
of	I:C0686217
the	I:C0686217
Glans	I:C0686217
Penis	I:C0686217
With	O
Topical	O
Imiquimod	O
Followed	O
by	O
Carbon	B:C0392251
Dioxide	I:C0392251
Laser	I:C0392251
Excision	O
.	O

Treatment	O
of	O
Carcinoma	O
In	I:C0686217
Situ	I:C0686217
of	I:C0686217
the	I:C0686217
Glans	I:C0686217
Penis	I:C0686217
With	O
Topical	O
Imiquimod	O
Followed	O
by	O
Carbon	O
Dioxide	I:C0392251
Laser	I:C0392251
Excision	B:C0728940
.	O

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	B:C0686217
in	I:C0686217
situ	I:C0686217
(	I:C0686217
CIS	I:C0686217
)	I:C0686217
of	I:C0686217
the	I:C0686217
glans	I:C0686217
penis	I:C0686217
(	O
erythroplasia	O
of	I:C0154089
Queyrat	I:C0154089
)	O
,	O
including	O
topical	O
chemotherapy	I:C1519552
or	O
immunotherapy	O
and	O
laser	O
or	O
surgical	O
excision	I:C0728940
.	O

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
(	I:C0686217
CIS	I:C0686217
)	I:C0686217
of	I:C0686217
the	I:C0686217
glans	I:C0686217
penis	I:C0686217
(	O
erythroplasia	B:C0154089
of	I:C0154089
Queyrat	I:C0154089
)	O
,	O
including	O
topical	O
chemotherapy	I:C1519552
or	O
immunotherapy	O
and	O
laser	O
or	O
surgical	O
excision	I:C0728940
.	O

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
(	I:C0686217
CIS	I:C0686217
)	I:C0686217
of	I:C0686217
the	I:C0686217
glans	I:C0686217
penis	I:C0686217
(	O
erythroplasia	O
of	I:C0154089
Queyrat	I:C0154089
)	O
,	O
including	O
topical	B:C1519552
chemotherapy	I:C1519552
or	O
immunotherapy	O
and	O
laser	O
or	O
surgical	O
excision	I:C0728940
.	O

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
(	I:C0686217
CIS	I:C0686217
)	I:C0686217
of	I:C0686217
the	I:C0686217
glans	I:C0686217
penis	I:C0686217
(	O
erythroplasia	O
of	I:C0154089
Queyrat	I:C0154089
)	O
,	O
including	O
topical	O
chemotherapy	I:C1519552
or	O
immunotherapy	B:C0021083
and	O
laser	O
or	O
surgical	O
excision	I:C0728940
.	O

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
(	I:C0686217
CIS	I:C0686217
)	I:C0686217
of	I:C0686217
the	I:C0686217
glans	I:C0686217
penis	I:C0686217
(	O
erythroplasia	O
of	I:C0154089
Queyrat	I:C0154089
)	O
,	O
including	O
topical	O
chemotherapy	I:C1519552
or	O
immunotherapy	O
and	O
laser	O
or	O
surgical	B:C0728940
excision	I:C0728940
.	O

We	O
evaluated	B:C0728940
the	O
efficacy	O
of	O
topical	O
imiquimod	O
(	O
IQ	O
)	O
followed	O
by	O
carbon	O
dioxide	I:C0392251
laser	I:C0392251
ablation	O
of	O
the	O
lesion	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
topical	O
imiquimod	O
(	O
IQ	O
)	O
followed	O
by	O
carbon	B:C0392251
dioxide	I:C0392251
laser	I:C0392251
ablation	O
of	O
the	O
lesion	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
topical	O
imiquimod	O
(	O
IQ	O
)	O
followed	O
by	O
carbon	O
dioxide	I:C0392251
laser	I:C0392251
ablation	B:C0348007
of	O
the	O
lesion	O
.	O

We	O
evaluated	O
the	O
efficacy	O
of	O
topical	O
imiquimod	O
(	O
IQ	O
)	O
followed	O
by	O
carbon	O
dioxide	I:C0392251
laser	I:C0392251
ablation	O
of	O
the	O
lesion	B:C0221198
.	O

From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
carcinoma	B:C0686217
in	I:C0686217
situ	I:C0686217
of	O
the	O
glans	O
were	O
treated	O
by	O
IQ	O
,	O
followed	O
by	O
carbon	O
dioxide	I:C0392251
laser	I:C0392251
ablation	O
.	O

From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
of	O
the	O
glans	O
were	O
treated	B:C0332293
by	O
IQ	O
,	O
followed	O
by	O
carbon	O
dioxide	I:C0392251
laser	I:C0392251
ablation	O
.	O

From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
of	O
the	O
glans	O
were	O
treated	O
by	O
IQ	O
,	O
followed	O
by	O
carbon	B:C0392251
dioxide	I:C0392251
laser	I:C0392251
ablation	O
.	O

From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
of	O
the	O
glans	O
were	O
treated	O
by	O
IQ	O
,	O
followed	O
by	O
carbon	O
dioxide	I:C0392251
laser	I:C0392251
ablation	B:C0348007
.	O

For	O
every	O
patient	O
,	O
we	O
performed	O
histologic	B:C0019637
examination	I:C0019637
before	O
and	O
after	O
IQ	O
.	O

Local	O
toxicity	B:C0013221
and	O
adverse	O
effects	I:C0879626
were	O
recorded	O
.	O

Local	O
toxicity	O
and	O
adverse	B:C0879626
effects	I:C0879626
were	O
recorded	O
.	O

After	O
treatment	O
,	O
histologic	B:C0019637
examination	I:C0019637
showed	O
no	O
residual	I:C0332652
tumor	I:C0332652
in	O
6	O
patients	O
(	O
complete	O
response	I:C4050307
[	O
complete	O
response	I:C4050307
]	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
2	O
patients	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
2	O
patients	O
.	O

After	O
treatment	O
,	O
histologic	O
examination	I:C0019637
showed	O
no	B:C0332652
residual	I:C0332652
tumor	I:C0332652
in	O
6	O
patients	O
(	O
complete	O
response	I:C4050307
[	O
complete	O
response	I:C4050307
]	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
2	O
patients	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
2	O
patients	O
.	O

After	O
treatment	O
,	O
histologic	O
examination	I:C0019637
showed	O
no	O
residual	I:C0332652
tumor	I:C0332652
in	O
6	O
patients	O
(	O
complete	B:C4050307
response	I:C4050307
[	O
complete	O
response	I:C4050307
]	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
2	O
patients	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
2	O
patients	O
.	O

After	O
treatment	O
,	O
histologic	O
examination	I:C0019637
showed	O
no	O
residual	I:C0332652
tumor	I:C0332652
in	O
6	O
patients	O
(	O
complete	O
response	I:C4050307
[	O
complete	B:C4050307
response	I:C4050307
]	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
2	O
patients	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
2	O
patients	O
.	O

After	O
treatment	O
,	O
histologic	O
examination	I:C0019637
showed	O
no	O
residual	I:C0332652
tumor	I:C0332652
in	O
6	O
patients	O
(	O
complete	O
response	I:C4050307
[	O
complete	O
response	I:C4050307
]	O
)	O
,	O
stable	B:C0677946
disease	I:C0677946
in	O
2	O
patients	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
2	O
patients	O
.	O

After	O
treatment	O
,	O
histologic	O
examination	I:C0019637
showed	O
no	O
residual	I:C0332652
tumor	I:C0332652
in	O
6	O
patients	O
(	O
complete	O
response	I:C4050307
[	O
complete	O
response	I:C4050307
]	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
2	O
patients	O
,	O
and	O
progressive	B:C1335499
disease	I:C1335499
in	O
2	O
patients	O
.	O

Those	O
with	O
a	O
complete	B:C4050307
response	I:C4050307
had	O
human	O
papillomavirus	I:C0021344
-	O
related	O
lesions	O
,	O
and	O
they	O
had	O
no	O
experienced	O
relapses	O
after	O
a	O
mean	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
26	O
months	O
.	O

Those	O
with	O
a	O
complete	O
response	I:C4050307
had	O
human	B:C0021344
papillomavirus	I:C0021344
-	O
related	O
lesions	O
,	O
and	O
they	O
had	O
no	O
experienced	O
relapses	O
after	O
a	O
mean	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
26	O
months	O
.	O

Those	O
with	O
a	O
complete	O
response	I:C4050307
had	O
human	O
papillomavirus	I:C0021344
-	O
related	O
lesions	B:C0221198
,	O
and	O
they	O
had	O
no	O
experienced	O
relapses	O
after	O
a	O
mean	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
26	O
months	O
.	O

Those	O
with	O
a	O
complete	O
response	I:C4050307
had	O
human	O
papillomavirus	I:C0021344
-	O
related	O
lesions	O
,	O
and	O
they	O
had	O
no	B:C1513916
experienced	O
relapses	O
after	O
a	O
mean	O
follow	O
-	I:C1522577
up	I:C1522577
of	O
26	O
months	O
.	O

Those	O
with	O
a	O
complete	O
response	I:C4050307
had	O
human	O
papillomavirus	I:C0021344
-	O
related	O
lesions	O
,	O
and	O
they	O
had	O
no	O
experienced	O
relapses	O
after	O
a	O
mean	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
of	O
26	O
months	O
.	O

The	O
2	O
patients	O
with	O
progressive	B:C1335499
disease	I:C1335499
underwent	O
total	O
penectomy	O
.	O

The	O
2	O
patients	O
with	O
progressive	O
disease	I:C1335499
underwent	O
total	O
penectomy	B:C0194708
.	O

All	O
patients	O
were	O
alive	B:C2584946
at	O
the	O
last	O
follow	O
-	I:C0260832
up	I:C0260832
examination	I:C0260832
.	O

All	O
patients	O
were	O
alive	O
at	O
the	O
last	O
follow	B:C0260832
-	I:C0260832
up	I:C0260832
examination	I:C0260832
.	O

All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	B:C0013221
(	O
burning	O
erythema	I:C0085624
)	O
but	O
no	O
major	O
adverse	O
effects	I:C0879626
.	O

All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	O
(	O
burning	B:C0085624
erythema	I:C0085624
)	O
but	O
no	O
major	O
adverse	O
effects	I:C0879626
.	O

All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	O
(	O
burning	O
erythema	I:C0085624
)	O
but	O
no	B:C1513916
major	O
adverse	O
effects	I:C0879626
.	O

All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	O
(	O
burning	O
erythema	I:C0085624
)	O
but	O
no	O
major	O
adverse	B:C0879626
effects	I:C0879626
.	O

Local	O
treatment	O
with	O
IQ	O
for	O
glans	O
carcinoma	B:C0686217
in	I:C0686217
situ	I:C0686217
is	O
effective	O
mainly	O
for	O
human	O
papillomavirus	I:C0021344
-	O
related	O
lesions	O
.	O

Local	O
treatment	O
with	O
IQ	O
for	O
glans	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
is	O
effective	O
mainly	O
for	O
human	B:C0021344
papillomavirus	I:C0021344
-	O
related	O
lesions	O
.	O

Local	O
treatment	O
with	O
IQ	O
for	O
glans	O
carcinoma	O
in	I:C0686217
situ	I:C0686217
is	O
effective	O
mainly	O
for	O
human	O
papillomavirus	I:C0021344
-	O
related	O
lesions	B:C0221198
.	O

The	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B:C0019637
examination	I:C0019637
findings	O
before	O
and	O
after	O
IQ	O
treatment	O
.	O

The	O
small	O
number	O
of	O
patients	O
,	O
owing	O
to	O
the	O
rarity	O
of	O
this	O
disease	B:C0012634
,	O
was	O
the	O
main	O
limitation	O
of	O
the	O
present	O
study	O
.	O

IQ	O
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
protocol	O
is	O
mandatory	O
because	O
of	O
the	O
lack	O
of	O
long	O
-	O
term	O
efficacy	O
data	O
.	O

IQ	O
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow	O
-	I:C1522577
up	I:C1522577
protocol	B:C0442711
is	O
mandatory	O
because	O
of	O
the	O
lack	O
of	O
long	O
-	O
term	O
efficacy	O
data	O
.	O

